Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the past decade, we have witnessed unprecedented changes and some remarkable advances that have enabled true personalized medicine. Nevertheless, many challenges in clinical cancer research remain and need to be overcome if we are to witness similar progress in the next decade. Such hurdles include, but are not limited to, clinical development and testing of multiple agents in combination, design of clinical trials to best accommodate the ever increasing knowledge of heterogeneity of the disease, regulatory challenges relating to drug development and trial design, and funding for basic research. With this in mind, we asked four leading cancer researchers from around the world, and who have been associated with the journal since its launch in November 2004 what, in their opinion, we have learnt over the past 10 years and how we should progress in the next 10 years.

Original publication

DOI

10.1038/nrclinonc.2014.153

Type

Journal article

Journal

Nat Rev Clin Oncol

Publication Date

11/2014

Volume

11

Pages

663 - 669

Keywords

Animals, Antineoplastic Agents, Biomedical Research, Clinical Trials as Topic, Humans, Medical Oncology, Molecular Targeted Therapy, Neoplasms, Precision Medicine